KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Work In Process: 2018-2025

Historic Work In Process for Acadia Pharmaceuticals (ACAD) over the last 8 years, with Sep 2025 value amounting to $76.9 million.

  • Acadia Pharmaceuticals' Work In Process rose 199.19% to $76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.9 million, marking a year-over-year increase of 199.19%. This contributed to the annual value of $69.7 million for FY2024, which is 1406.94% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Work In Process stood at $76.9 million for Q3 2025, which was down 8.90% from $84.4 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Work In Process' 5-year high stood at $84.4 million during Q2 2025, with a 5-year trough of $4.6 million in Q3 2023.
  • Moreover, its 3-year median value for Work In Process was $14.5 million (2024), whereas its average is $34.2 million.
  • Its Work In Process has fluctuated over the past 5 years, first fell by 27.24% in 2022, then skyrocketed by 1,406.94% in 2024.
  • Acadia Pharmaceuticals' Work In Process (Quarterly) stood at $6.8 million in 2021, then dropped by 27.24% to $4.9 million in 2022, then declined by 6.01% to $4.6 million in 2023, then soared by 1,406.94% to $69.7 million in 2024, then spiked by 199.19% to $76.9 million in 2025.
  • Its last three reported values are $76.9 million in Q3 2025, $84.4 million for Q2 2025, and $80.0 million during Q1 2025.